Table 3.
| Table 3a – HPV DNA detection at baseline and follow up for all subjects | ||||||
|---|---|---|---|---|---|---|
| N | HPV DNA+ # (%) |
HR* HPV DNA+ # (%) |
LR* HPV DNA+ # (%) |
Multiple HPV Types DNA+ # (%) |
Multiple HR* HPV Types DNA+ # (%) |
|
| Baseline | 146 | 97 (66) | 90 (62) | 36 (25) | 61 (42) | 46 (32) |
| Week 24 | 119 | 73 (61) | 63 (53) | 27 (23) | 38 (32) | 31 (26) |
| Week 48 | 104 | 63 (61) | 56 (54) | 29 (28) | 33 (32) | 21 (20) |
| Week 96 | 94 | 46 (49) | 37 (39) | 19 (20) | 23 (24) | 15 (16) |
| Duration of follow-up** (every 24 weeks) |
OR(CI)** P-value |
0.87 (0.77, 1.00) 0.043 |
0.83 (0.74, 0.94) 0.002 |
0.99(0.85, 1.15) 0.907 |
0.87 (0.78, 0.97) 0.013 |
0.83 (0.72, 0.95) 0.009 |
| Significant Covariates (P<0.05) | ||||||
| Baseline CD4 count (every 50 cells) |
OR(CI)** P-value |
0.89 (0.81, 0.96) 0.005 |
0.90 (0.83, 0.98) 0.018 |
0.90(0.82,0.99) 0.039 |
0.88 (0.79, 0.97) 0.011 |
0.90 (0.81, 1.00) 0.050 |
| CCA* at Baseline | OR(CI)** P-value |
- NS |
2.26 (1.01, 5.09) 0.049 |
- NS |
2.42 (1.09, 5.41) 0.031 |
2.70 (1.20, 6.06) 0.017 |
| Table 3b – HPV DNA detection at baseline and follow up for subjects with data at all time points | ||||||
| N | HPV DNA+ # (%) |
HR* HPV DNA+ # (%) |
LR* HPV DNA+ # (%) |
Multiple HPV Types DNA+ # (%) |
Multiple HR* HPV Types DNA+ # (%) |
|
| Baseline | 72 | 43 (60) | 40 (56) | 12 (17) | 26 (36) | 20 (28) |
| Week 24 | 72 | 39 (54) | 35 (49) | 11 (15) | 18 (25) | 14 (19) |
| Week 48 | 72 | 40 (56) | 36 (50) | 15(21) | 19 (26) | 11 (15) |
| Week 96 | 72 | 36 (50) | 30 (42) | 14 (19) | 16 (22) | 11 (15) |
| Duration of follow-up** (every 24 weeks) |
OR(CI)** P-value |
0.86 (0.71, 1.04) 0.113 |
0.83 (0.71, 0.97) 0.017 |
1.04(0.85, 1.27) 0.695 |
0.84 (0.71, 1.00) 0.047 |
0.77 (0.61, 0.98) 0.037 |
| Significant Covariates (P<0.05) | ||||||
| Baseline CD4 count (every 50 cells) |
OR(CI)** P-value |
0.76 (0.67, 0.87) <0.001 |
0.79 (0.69, 0.91) 0.002 |
- NS |
0.80 (0.68, 0.94) 0.008 |
0.80 (0.65, 0.99) 0.043 |
| CCA* at Baseline | OR(CI)** P-value |
- NS |
- NS |
- NS |
4.51(1.36,14.99) 0.015 |
7.67(1.69,34.73) 0.009 |
| Age >35 at Baseline | OR(CI)** P-value |
0.22 (0.09, 0.55) 0.001 |
0.23 (0.08, 0.62) 0.004 |
- NS |
- NS |
- NS |
*
HR – high cancer risk HPV type; LR – low cancer risk HPV type; CCA – cervical cytological abnormality (see methods section)
**
Based on the logistic random-effect mixed models; OR(CI)- Odds Ratio (95% Confidence Interval)